LEUPRORELIN
leuprorelin acetate 45 mg modified release injection [1 syringe] (&) inert substance
diluent [1 syringe], 1 pack
Manner of administration:Injection
Restriction
Indication: Central precocious puberty
Treatment phase: Initial treatment
Restriction
Indication: Central precocious puberty
Treatment phase: Continuing treatment with this drug, or, switching gonadotropin releasing hormone
analogue therapy
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 1 | # of repeats: 0 | DPMQ: $1,377.51 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Eligard 6 month | |||||
leuprorelin acetate 45 mg modified release injection [1 syringe] (&) inert substance
diluent [1 syringe], 1 pack
Manner of administration:Injection
Restriction
Indication: Locally advanced (stage C) or metastatic (stage D) carcinoma of the prostate
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 1 | # of repeats: 0 | DPMQ: $1,377.51 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Eligard 6 month | |||||